Karani Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Karani Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2.05M	Sell	11,555 -3,690	-24%	-$704K	2.95%	19
2023 Q2	$2.9M	Sell	15,245 -471	-3%	-$93.4K	2.92%	20
2023 Q1	$3.15M	Buy	15,716 +88	+0.6%	+$18.5K	3.33%	16
2022 Q4	$3.71M	Sell	15,628 -4,538	-23%	-$968K	4.33%	8
2022 Q3	$4.04M	Sell	20,166 -9,819	-33%	-$1.87M	4.09%	12
2022 Q2	$4.37M	Sell	29,985 -6,975	-19%	-$990K	4.04%	12
2022 Q1	$6.04M	Buy	36,960 +2,285	+7%	+$348K	3.26%	15
2021 Q4	$5.88M	Buy	34,675 +2,186	+7%	+$406K	2.91%	17
2021 Q3	$6.13M	Buy	+32,489	New	+$6.09M	2.98%	16
2021 Q2	–	Sell	-31,587	Closed	-$4.46M	–	42
2021 Q1	$4.46M	Buy	31,587 +12	+0%	+$1.81K	2.63%	20
2020 Q4	$4.1M	Buy	31,575 +4,885	+18%	+$652K	2.43%	18
2020 Q3	$3.89M	Hold	26,690	–	–	2.61%	19
2020 Q2	$3.95M	Buy	+26,690	New	+$3.6M	3.06%	15

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Karani Asset Management's ALNY Position: Q3 2023 in Review

Karani Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 24% in Q3 2023, selling an estimated $704K and leaving 11,555 shares worth $2.05M. The position accounts for 2.95% of the portfolio, ranked #19.

Karani Asset Management first reported a position in ALNY in Q2 2020 and has held it in 13 quarters since. The position peaked at $6.13M in Q3 2021. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

Karani Asset Management held 11,555 shares of Alnylam Pharmaceuticals worth $2.05M as of Q3 2023.
Karani Asset Management sold 3,690 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $704K.
Alnylam Pharmaceuticals made up 2.95% of Karani Asset Management's portfolio in Q3 2023, its #19 holding.
Karani Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
Karani Asset Management's Alnylam Pharmaceuticals position peaked at $6.13M in Q3 2021.
453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Karani Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.